EUVIMEDEUVIMED entdecken
Crossref

Butyrate receptor HCAR2/GPR109A controls imiquimod-induced psoriasis-like skin inflammation

Lucija Leko iD, Darija Šimić iD, Timna Valera Martins iD, Gabriel Victor Lucena da Silva iD, Isabelle Maillet iD, Florence Savigny iD, Lara Vuksan, Dorian de Moura Rodrigues iD, Marc Le Bert iD, Stefan Offermanns iD, Nicolas Riteau iD, Dieudonnée Togbe iD und 4 weitere

The Journal of Immunology · 2025

DOI: 10.1093/jimmun/vkaf069 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Lucija Leko und 15 weiteren Autor:innen. Beteiligte Einrichtung: Immuno-Neuro Modulation, UMR7355 INEM, National Centre for Scientific Research and University of Orléans, Orléans Cedex 2, France. Hauptthemen laut MEDLINE: Imiquimod, Psoriasis, Receptors, G-Protein-Coupled. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Centre National de la Recherche Scientifique, University of Orléans, and European, Region Centre-Val de Loire.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriasis is a chronic inflammatory skin disorder characterized by aberrant keratinocyte proliferation and immune cell infiltration with upregulation of inflammatory cytokines. Here, we examined the contribution of HCAR2 encoding for the short-chain fatty acid receptor GPR109A. Human and mouse RNA sequencing public datasets reveal elevated HCAR2 gene expression in psoriatic as compared with healthy skin, both in keratinocytes and myeloid cells. Immunostaining and flow cytometry of imiquimod-induced psoriatic-like lesions in Hcar2-mRFP reporter mice showed increased GPR109A expression by keratinocytes and inflammatory cells. GPR109A-deficient mice demonstrated a more severe imiquimod-induced psoriasis-like response than wild-type mice, with exacerbated epidermal hyperplasia, dermal inflammatory cell infiltration, and increased inflammatory mediators myeloperoxidase, CXCL5, LCN2, interleukin (IL)-1β, IL-6, IL-23, and IL-17A. Conversely, topical administration of sodium butyrate reduced imiquimod-induced skin inflammation in wild-type mice, but not in GPR109A-deficient mice. Mechanistically, GPR109A agonist butyrate inhibits histone deacetylase 3, thus inhibiting IL-1β and the inflammatory IL-1β/IL-23/IL-17A axis in imiquimod-induced skin inflammation. Therefore, GPR109A may have a protective role in psoriasis pathogenesis, supporting a potential therapeutic benefit of sodium butyrate administration or other GPR109A agonists for treating psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImiquimodPsoriasisReceptors, G-Protein-CoupledInflammationAnimalsMiceHumansKeratinocytesMyeloid CellsButyric AcidAdministration, TopicalTranscriptomeMice, Inbred C57BLMice, KnockoutSkinSingle-Cell Gene Expression Analysis

Stichwörter der Autor:innen

autoimmunityinflammationmonocytes/macrophagesneutrophilsskin

Substanzen

ImiquimodHcar2 protein, mouseReceptors, G-Protein-CoupledButyric Acid

Autor:innen und Institutionen

  • Immuno-Neuro Modulation, UMR7355 INEM, National Centre for Scientific Research and University of Orléans, Orléans Cedex 2, France.
  • Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
  • Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
  • Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
  • Center for Molecular Medicine, Goethe University Frankfurt, Frankfurt, Germany.
  • Immune Health Laboratory, "Regulation of Host Responses and Immune Health" IRL2029, French National Centre for Scientific Research and Ribeirão Preto Medical School, São Paulo University, Ribeirão Preto, Brazil.

ORCID-Profile: Lucija Leko, Darija Šimić, Timna Valera Martins, Gabriel Victor Lucena da Silva, Isabelle Maillet, Florence Savigny, Dorian de Moura Rodrigues, Marc Le Bert, Stefan Offermanns, Nicolas Riteau, Dieudonnée Togbe, Valerie F Quesniaux, Remo Castro Russo, José Carlos Alves-Filho, Bernhard Ryffel

Förderung

  • Centre National de la Recherche Scientifique
  • University of Orléans, and European
  • Region Centre-Val de Loire
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Fundação de Amparo a Pesquisa de Minas Gerais
  • Rede Mineira de Pesquisa Translacional em Imunobiológicos e Biofármacos no Câncer
  • Le Studium Loire Valley Institute for Advanced Studies and Biopharmaceuticals Programs
  • FEDER Exposome&Inflammation

Zitieren

APA

Leko, L., Šimić, D., Martins, T. V., da Silva, G. V. L., Maillet, I., Savigny, F., Vuksan, L., de Moura Rodrigues, D., Le Bert, M., Offermanns, S., Riteau, N., Togbe, D., Quesniaux, V. F., Russo, R. C., Alves-Filho, J. C., & Ryffel, B. (2025). Butyrate receptor HCAR2/GPR109A controls imiquimod-induced psoriasis-like skin inflammation. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf069

Vancouver

Leko L, Šimić D, Martins TV, da Silva GVL, Maillet I, Savigny F, et al. Butyrate receptor HCAR2/GPR109A controls imiquimod-induced psoriasis-like skin inflammation. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf069

BibTeX
@article{Leko2025,
  author = {Leko, Lucija and Šimić, Darija and Martins, Timna Valera and da Silva, Gabriel Victor Lucena and Maillet, Isabelle and Savigny, Florence and Vuksan, Lara and de Moura Rodrigues, Dorian and Le Bert, Marc and Offermanns, Stefan and Riteau, Nicolas and Togbe, Dieudonnée and Quesniaux, Valerie F and Russo, Remo Castro and Alves-Filho, José Carlos and Ryffel, Bernhard},
  title = {Butyrate receptor HCAR2/GPR109A controls imiquimod-induced psoriasis-like skin inflammation},
  journal = {The Journal of Immunology},
  year = {2025},
  doi = {10.1093/jimmun/vkaf069}
}
Kostenlos starten →